Is a contrarian leader good for the FDA?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning. Today, we have the highly anticipated CagriSema results. We also see Ionis win approval for a new drug, which means it will start bringing its commercialization efforts in-house. And the FDA says tirzepatide is no longer in shortage.

Read the rest…